Abstract: Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the first organometallic drug: a ferrocenyl group covalently flanked by a 4-aminoquinoline and a basic alkylamine. FQ is able to overcome the CQ resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria. After fifteen years of effort, it is now possible to propose a multifactorial mechanism of action of FQ by its capacity to target lipids, to inhibit the formation of hemozoin and to generate reactive oxygen species.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Dubar, F.; Khalife, J.; Brocard, J.; Dive, D.; Biot, C. Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action. Molecules 2008, 13, 2900-2907.
Dubar F, Khalife J, Brocard J, Dive D, Biot C. Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action. Molecules. 2008; 13(11):2900-2907.
Dubar, Faustine; Khalife, Jamal; Brocard, Jacques; Dive, Daniel; Biot, Christophe. 2008. "Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action." Molecules 13, no. 11: 2900-2907.